Plaque psoriasis
Immunology· 14 reviewed drugs· 29291 cited findings behind them
What the regulatory reviews cover
This library contains regulatory review documents for several drugs indicated for the treatment of plaque psoriasis. These include Tremfya, Bimzelx, Cosentyx, Skyrizi, Sotyktu, Stelara, Otezla, Taltz, Cimzia, Kyntheum, tildrakizumab, Skilarence, and Nordimet.
The review documents report various efficacy and safety outcomes. For instance, Bimzelx showed a PASI 90 response rate of 90.8%, while the placebo group had a PASI 90 response rate of 4.8%. Cosentyx demonstrated an IGA of clear or almost clear in 65% of patients. Taltz achieved a PASI-75 response rate of 90%. Sotyktu achieved statistical significance for co-primary endpoints (sPGA 0/1 and PASI 75). It is important to note that these figures are derived from different clinical trials and are not directly comparable across drugs.
The drugs — one cited result each
| Tremfya Johnson & Johnson | IGA 0/1 response rate: 100.0 Johnson & Johnson — Tremfya FDA Review, p.243 |
| Bimzelx UCB SA | PASI 90 response rate: 90.8 UCB S A — Bimzelx EMA EPAR public assessment report (EMEA/H/, p.214 |
| Cosentyx Novartis AG | IGA of clear or almost clear: 65 NOVARTIS PHARMS CORP — Cosentyx FDA Review (NDA/BLA 125504,, p.25 |
| Skyrizi AbbVie Inc. | sPGA 0 or 1 response rate (%): 61 ABBVIE INC — Skyrizi FDA Review (NDA/BLA 761105, 2024), p.21 |
| Sotyktu Bristol-Myers Squibb Company | Statistical significance for co-primary endpoints (sPGA 0/1 and PASI 75): achieved Bristol-Myers Squibb Company — Sotyktu EMA EPAR public asses, p.112 |
| Stelara Johnson & Johnson | Clinical Response at Week 6 (Induction Study 3002): 55.5 % Johnson & Johnson — Stelara FDA Review (BLA761044, ORIG 1, 2, p.114 |
| Otezla Amgen Inc. | 2270 cited findings on the drug page → |
| Taltz Eli Lilly and Company | PASI-75 response rate: 90% Eli Lilly and Company — Taltz FDA Review (BLA125521, ORIG 1,, p.109 |
| Cimzia UCB SA | sPGA 0 or 1 at Week 12 (210 mg q2wk): 79% UCB INC — Cimzia FDA Review (NDA/BLA 125160, 2021), p.82 |
| Kyntheum LEO A S | 737 cited findings on the drug page → |
| tildrakizumab Almirall S A | PASI 75 response rate (tildrakizumab): 63.8 Almirall S A — Ilumetri EMA EPAR public assessment report (E, p.50 |
| Spevigo LEO A S | 565 cited findings on the drug page → |
| Skilarence Almirall S A | PASI 75 response rate (Skilarence): 42.7 Almirall S A — Skilarence EMA EPAR public assessment report, p.60 |
| Nordimet Nordic B V | PASI 75 response rate: 41 Nordic B V — Nordimet EMA EPAR variation assessment report (, p.20 |
Different drugs were studied in different trials — these figures are not head-to-head comparisons.
Explore the full evidence
Every finding behind these drugs — searchable, comparable and answerable in plain language — is in the Immunology research library →
Lists reflect the regulatory review documents in this library, not all therapies that exist. Educational reference only — not medical or investment advice.